{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T13:55:03Z","timestamp":1752674103769},"reference-count":9,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,23]]},"DOI":"10.7759\/cureus.52816","type":"journal-article","created":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T01:06:49Z","timestamp":1706058409000},"source":"Crossref","is-referenced-by-count":1,"title":["Toxic Erythema of Chemotherapy, Vasculitic Eruption With Malignant Intertrigo Characteristics, and Superimposed Infection Post-bevacizumab Initiation"],"prefix":"10.7759","author":[{"given":"Kristin N","family":"Slater","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trevor","family":"Nessel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisca","family":"Kartono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1272\/jnms.JNMS.2022_89-221","article-title":"Current trends in anti-cancer molecular targeted therapies: renal complications and their histological features","volume":"89","author":"Tonooka A","year":"2022","unstructured":"Tonooka A, Ohashi R. Current trends in anti-cancer molecular targeted therapies: renal complications and their histological features. J Nippon Med Sch. 2022, 89:128-38. 10.1272\/jnms.JNMS.2022_89-221","journal-title":"J Nippon Med Sch"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000017870","article-title":"Bevacizumab-induced immunoglobulin A vasculitis with nephritis: a case report","volume":"98","author":"Endo Y","year":"2019","unstructured":"Endo Y, Negishi K, Hirayama K, Suzuki H, Shimizu A. Bevacizumab-induced immunoglobulin A vasculitis with nephritis: a case report. Medicine (Baltimore). 2019, 98:e17870. 10.1097\/MD.0000000000017870","journal-title":"Medicine (Baltimore)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjog.2018.08.026","article-title":"Drug-induced aortitis in a patient with ovarian cancer treated with bevacizumab combination therapy","volume":"57","author":"Hiranuma K","year":"2018","unstructured":"Hiranuma K, Kusunoki S, Fujino K, Hirayama T, Ota T, Terao Y. Drug-induced aortitis in a patient with ovarian cancer treated with bevacizumab combination therapy. Taiwan J Obstet Gynecol. 2018, 57:750-2. 10.1016\/j.tjog.2018.08.026","journal-title":"Taiwan J Obstet Gynecol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2014.02.010","article-title":"Antiangiogenic agents and the skin: cutaneous adverse effects of sorafenib, sunitinib, and bevacizumab","volume":"105","author":"Ara M","year":"2014","unstructured":"Ara M, Pastushenko E. Antiangiogenic agents and the skin: cutaneous adverse effects of sorafenib, sunitinib, and bevacizumab. Actas Dermosifiliogr. 2014, 105:900-12. 10.1016\/j.ad.2014.02.010","journal-title":"Actas Dermosifiliogr"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100342","article-title":"Safety and activity of alectinib plus bevacizumab in patients with advanced ALK-rearranged non-small-cell lung cancer: a phase I\/II study","volume":"7","author":"Lin JJ","year":"2022","unstructured":"Lin JJ, Muzikansky A, Kennedy E, et al.. Safety and activity of alectinib plus bevacizumab in patients with advanced ALK-rearranged non-small-cell lung cancer: a phase I\/II study. ESMO Open. 2022, 7:100342. 10.1016\/j.esmoop.2021.100342","journal-title":"ESMO Open"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2027187","article-title":"First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer","volume":"383","author":"Shaw AT","year":"2020","unstructured":"Shaw AT, Bauer TM, de Marinis F, et al.. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med. 2020, 383:2018-29. 10.1056\/NEJMoa2027187","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1200\/PO.20.00271","article-title":"Lorlatinib and bevacizumab activity in ALK-rearranged lung cancers after lorlatinib progression","volume":"4","author":"Choudhury NJ","year":"2020","unstructured":"Choudhury NJ, Young RJ, Sellitti M, Miller A, Drilon A. Lorlatinib and bevacizumab activity in ALK-rearranged lung cancers after lorlatinib progression. JCO Precis Oncol. 2020, 4:10.1200\/PO.20.00271","journal-title":"JCO Precis Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2016.08.016","article-title":"Malignant intertrigo: a subset of toxic erythema of chemotherapy requiring recognition","volume":"2","author":"Smith SM","year":"2016","unstructured":"Smith SM, Milam PB, Fabbro SK, Gru AA, Kaffenberger BH. Malignant intertrigo: a subset of toxic erythema of chemotherapy requiring recognition. JAAD Case Rep. 2016, 2:476-81. 10.1016\/j.jdcr.2016.08.016","journal-title":"JAAD Case Rep"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.33937","article-title":"Painful foot lesions: a case report","volume":"15","author":"Lockard TJ","year":"2023","unstructured":"Lockard TJ, Swali RN, Javid Whitley M. Painful foot lesions: a case report. Cureus. 2023, 15:e33937. 10.7759\/cureus.33937","journal-title":"Cureus"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/220309-toxic-erythema-of-chemotherapy-vasculitic-eruption-with-malignant-intertrigo-characteristics-and-superimposed-infection-post-bevacizumab-initiation","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:12:17Z","timestamp":1707509537000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/220309-toxic-erythema-of-chemotherapy-vasculitic-eruption-with-malignant-intertrigo-characteristics-and-superimposed-infection-post-bevacizumab-initiation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,23]]},"references-count":9,"URL":"https:\/\/doi.org\/10.7759\/cureus.52816","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1,23]]}}}